Acumen Pharmaceuticals reported its financial results for the year ended December 31, 2024, with cash, cash equivalents, and marketable securities totaling $231.5 million. This capital is projected to fund operating expenses and capital expenditure requirements into the first half of 2027. The company reported a net loss of $28.8 million for Q1 2025, contributing to an accumulated deficit of $353.9 million.
The company confirmed the completion of enrollment for its Phase 2 ALTITUDE-AD study of sabirnetug for early Alzheimer’s disease. Topline results from this pivotal trial are anticipated in late 2026. This operational achievement was noted as being ahead of schedule.
Additionally, topline results from the Phase 1 study investigating a subcutaneous sabirnetug formulation were reported, supporting further development of this dosing option. Research and Development expenses increased by $12.9 million in Q1 2025 compared to Q1 2024, primarily due to increased CRO costs and manufacturing for the ALTITUDE-AD trial.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.